NASDAQ: AMPH | Healthcare / Drug Manufacturers / USA |
45.89 | +1.02 | +2.27% | Vol 351.35K | 1Y Perf 57.22% |
Oct 4th, 2023 16:00 DELAYED |
BID | 45.96 | ASK | 47.99 | ||
Open | 44.89 | Previous Close | 44.87 | ||
Pre-Market | - | After-Market | 45.96 | ||
- - | 0.07 0.15% |
Target Price | 38.00 | Analyst Rating | Strong Buy 1.50 | |
Potential % | -17.19 | Finscreener Ranking | ★★★+ 51.47 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★★ 55.51 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★★+ 64.25 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 46.77 | Earnings Rating | Strong Buy | |
Market Cap | 2.24B | Earnings Date | 6th Nov 2023 | |
Alpha | 0.01 | Standard Deviation | 0.12 | |
Beta | 0.87 |
Today's Price Range 44.0846.21 | 52W Range 26.7667.66 | 5 Year PE Ratio Range -139.30921.10 |
Summary:
Sell
Technical Indicators: | Sell |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | -3.51% | ||
1 Month | -17.72% | ||
3 Months | -22.14% | ||
6 Months | 15.82% | ||
1 Year | 57.22% | ||
3 Years | 136.16% | ||
5 Years | 135.04% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 6.12 | |||
ROE last 12 Months | 17.76 | |||
ROA (5Y Avg) | 3.30 | |||
ROA last 12 Months | 12.08 | |||
ROC (5Y Avg) | 3.05 | |||
ROC last 12 Months | 13.57 | |||
Return on invested Capital Q | 2.62 | |||
Return on invested Capital Y | 3.64 | |||
Assets Turnover | 0.60 | |||
Receivables Turnover | 4.70 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
19.20 | ||||
2.76 | ||||
3.72 | ||||
13.10 | ||||
24.80 | ||||
2.20 | ||||
2.98 | ||||
10.45 | ||||
1.31B | ||||
Forward PE | 14.15 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
2.70 | ||||
3.80 | ||||
0.16 | ||||
0.20 | ||||
68.70 | ||||
Leverage Ratio | 1.50 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
48.30 | ||||
21.30 | ||||
27.10 | ||||
8.00 | ||||
15.79 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
363.96M | ||||
7.53 | ||||
11.44 | ||||
12.28 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2023 | 0.52 | 0.58 | 11.54 |
Q01 2023 | 0.40 | 0.52 | 30.00 |
Q04 2022 | 0.34 | 0.67 | 97.06 |
Q03 2022 | 0.32 | 0.32 | 0.00 |
Q02 2022 | 0.30 | 0.33 | 10.00 |
Q01 2022 | 0.33 | 0.47 | 42.42 |
Q04 2021 | 0.38 | 0.42 | 10.53 |
Q03 2021 | 0.22 | 0.46 | 109.09 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
9/2023 QR | 0.67 | 6.35 | Positive |
12/2023 QR | 0.72 | 14.29 | Positive |
12/2023 FY | 2.50 | 7.30 | Positive |
12/2024 FY | 3.25 | 21.72 | Positive |
Next Report Date | 6th Nov 2023 |
Estimated EPS Next Report | 0.67 |
Estimates Count | 3 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 351.35K |
Shares Outstanding | 48.86K |
Shares Float | 34.98M |
Trades Count | 8.05K |
Dollar Volume | 16.08M |
Avg. Volume | 480.93K |
Avg. Weekly Volume | 398.80K |
Avg. Monthly Volume | 608.71K |
Avg. Quarterly Volume | 435.29K |
Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) stock closed at 44.87 per share at the end of the most recent trading day (a -1.9% change compared to the prior day closing price) with a volume of 413.32K shares and market capitalization of 2.24B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 2027 people. Amphastar Pharmaceuticals Inc. CEO is Jack Yongfeng Zhang.
The one-year performance of Amphastar Pharmaceuticals Inc. stock is 57.22%, while year-to-date (YTD) performance is 60.14%. AMPH stock has a five-year performance of 135.04%. Its 52-week range is between 26.76 and 67.66, which gives AMPH stock a 52-week price range ratio of 46.77%
Amphastar Pharmaceuticals Inc. currently has a PE ratio of 19.20, a price-to-book (PB) ratio of 2.76, a price-to-sale (PS) ratio of 3.72, a price to cashflow ratio of 13.10, a PEG ratio of -, a ROA of 12.08%, a ROC of 13.57% and a ROE of 17.76%. The company’s profit margin is 15.79%, its EBITDA margin is 27.10%, and its revenue ttm is $363.96 Million , which makes it $7.53 revenue per share.
Of the last four earnings reports from Amphastar Pharmaceuticals Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.67 for the next earnings report. Amphastar Pharmaceuticals Inc.’s next earnings report date is 06th Nov 2023.
The consensus rating of Wall Street analysts for Amphastar Pharmaceuticals Inc. is Strong Buy (1.5), with a target price of $38, which is -17.19% compared to the current price. The earnings rating for Amphastar Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Amphastar Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Amphastar Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 9.49, ATR14 : 1.72, CCI20 : -96.33, Chaikin Money Flow : -0.34, MACD : -2.01, Money Flow Index : 41.04, ROC : -1.97, RSI : 34.34, STOCH (14,3) : 25.38, STOCH RSI : 0.17, UO : 46.40, Williams %R : -74.62), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Amphastar Pharmaceuticals Inc. in the last 12-months were: Deflin Gayle (Sold 6 019 shares of value $263 606 ), Floyd F. Petersen (Sold 2 491 shares of value $81 472 ), Jacob Liawatidewi (Option Excercise at a value of $333 674), Jacob Liawatidewi (Sold 16 494 shares of value $677 748 ), Lee Howard (Option Excercise at a value of $278 373), Lee Howard (Option Exercise at a value of $278 373), Lee Howard (Sold 16 679 shares of value $750 960 ), Peters William (Option Excercise at a value of $2 471 861), Peters William (Sold 163 393 shares of value $7 707 376 ), PETERS WILLIAM J (Option Exercise at a value of $146 850), PETERS WILLIAM J (Sold 11 000 shares of value $509 859 ), Petersen Floyd (Sold 6 991 shares of value $281 665 ), Prins Richard (Sold 0 shares of value $-166 900 ), Prins Richard (Sold 16 163 shares of value $771 715 ), William J. Peters (Option Excercise at a value of $722 744), William J. Peters (Sold 68 032 shares of value $2 577 781 ), Yakob Liawatidewi (Option Excercise at a value of $761 768), Yakob Liawatidewi (Sold 45 310 shares of value $2 208 742 ), Zasloff Michael (Sold 20 259 shares of value $1 046 420 ), Zhou Rong (Sold 0 shares of value $-609 018 ), Zhou Rong (Option Exercise at a value of $72 000), Zhou Rong (Sold 20 000 shares of value $942 250 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Amphastar Pharmaceuticals Inc is a specialty pharmaceutical company engaged in developing, manufacturing, marketing and selling generic and proprietary injectable and inhalation products. The business activities are operated through two reportable segments namely finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, naloxone, lidocaine, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API. Its products are used in hospitals or urgent care clinical settings. Geographically the business presence of the firm is seen in the United States and France of which the US accounts for the majority of revenue.
CEO: Jack Yongfeng Zhang
Telephone: +1 909 980-9484
Address: 11570 6th Street, Rancho Cucamonga 91730, CA, US
Number of employees: 2 027
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.